Canagliflozin review – safety and efficacy profile in patients with T2DM
Haroon Jakher,1 Tara I Chang,2 Marilyn Tan,3 Kenneth W Mahaffey4 1Department of Medicine, Stanford University School of Medicine, Palo Alto, CA, USA; 2Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA, USA; 3Division of Endocrinology, Department of...
Guardado en:
Autores principales: | Jakher H, Chang TI, Tan M, Mahaffey KW |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d4b21752c4a54c98aaec3e0d8e547680 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis
por: Seko Y, et al.
Publicado: (2018) -
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
por: Simes BC, et al.
Publicado: (2019) -
Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome
por: Davies MJ, et al.
Publicado: (2017) -
Investigation of the Effect of Canagliflozin on the Disposition Index, a Marker of Pancreatic Beta Cell Function, in Patients with Type 2 Diabetes
por: Takahara M, et al.
Publicado: (2020) -
Comparative Analysis of the Preventive Effects of Canagliflozin, a Sodium-Glucose Co-Transporter-2 Inhibitor, on Body Weight Gain Between Oral Gavage and Dietary Administration by Focusing on Fatty Acid Metabolism
por: Kawarasaki S, et al.
Publicado: (2020)